The Role of Cancer Stem Cells in Glioblastoma Treatment:  New Strategies for Targeted Therapy

Kaize Yan

doi:10.62051/7tjwpt29

Authors

Kaize Yan

DOI:

https://doi.org/10.62051/7tjwpt29

Keywords:

Glioblastoma; cancer stem cells; Wnt/beta-catenin signaling pathway; Notch signaling pathway.

Abstract

Glioblastoma (GBM) is a highly aggressive and recurrent brain tumor for which traditional treatments often yield limited success. According to recent research, cancer stem cells (CSCs) are essential for the development, spread, and resistance to treatment of GBM. This review systematically explores the critical roles of cancer stem cells (CSCs) in glioblastoma (GBM), especially through the regulation of Notch, Wnt, and Hh signaling pathways. The maintenance of CSC properties is primarily dependent on the Notch, Wnt, and Hedgehog (Hh) signaling pathways. This review explores the mechanisms of these pathways in GBM, discusses multi-targeted combination therapies, and highlights emerging strategies and drugs for targeted therapy. The results indicate that targeting Notch, Wnt, and Hh pathways can effectively suppress CSC proliferation and invasiveness in GBM, significantly delaying tumor recurrence. Future research should further explore the clinical potential of these pathway inhibitors and develop more specific targeted therapies to improve GBM treatment outcomes and patient prognosis.

Downloads

Download data is not yet available.

References

[1] Yin W, Wang J, Jiang L, James Kang Y. Cancer and stem cells. Exp Biol Med (Maywood), 2021, 246(16):1791-1801.

[2] Li R, Liu X, Huang X, Zhang D, Chen Z, Zhang J, Bai R, Zhang S, Zhao H, Xu Z, Zeng L, Zhuang L, Wen S, Wu S, Li M, Zuo Z, Lin J, Lin D, Zheng J. Single-cell transcriptomic analysis deciphers heterogenous cancer stem-like cells in colorectal cancer and their organ-specific metastasis. Gut, 2024, 73(3):470-484.

[3] Wang J, Yu H, Dong W, Zhang C, Hu M, Ma W, Jiang X, Li H, Yang P, Xiang D. N6-Methyladenosine-Mediated Up-Regulation of FZD10 Regulates Liver Cancer Stem Cells' Properties and Lenvatinib Resistance Through WNT/β-Catenin and Hippo Signaling Pathways. Gastroenterology, 2023, 164(6):990-1005.

[4] Wang S, Lei Z, Liu W, Xiong J, Shi Y, Yang L, Gao Q, Le K, Zhang B. RCC2 promotes prostate cancer cell proliferation and migration through Hh/GLI1 signaling pathway and cancer stem-like cells. Biol Direct, 2023, 18(1):80.

[5] Piper K, DePledge L, Karsy M, Cobbs C. Glioma Stem Cells as Immunotherapeutic Targets: Advancements and Challenges. Front Oncol, 2021, 11:615704.

[6] Li Y, Wang Z, Ajani JA, Song S. Drug resistance and Cancer stem cells. Cell Commun Signal, 2021, 19(1):19.

[7] Clevers H, Nusse R. Wnt/β-catenin signaling and disease. Cell, 2012, 149(6):1192-1205.

[8] Almiron Bonnin DA, Havrda MC, Lee MC, Liu H, Zhang Z, Nguyen LN, Harrington LX, Hassanpour S, Cheng C, Israel MA. Secretion-mediated STAT3 activation promotes self-renewal of glioma stem-like cells during hypoxia. Oncogene, 2018, 37(8):1107-1118.

[9] Wang Y, Gao G, Wei X, Zhang Y, Yu J. UBE2T Promotes Temozolomide Resistance of Glioblastoma Through Regulating the Wnt/β-Catenin Signaling Pathway. Drug Des Devel Ther, 2023, 17:1357-1369.

[10] Sun Y, Wang W, Zhao C. Frizzled Receptors in Tumors, Focusing on Signaling, Roles, Modulation Mechanisms, and Targeted Therapies. Oncol Res, 2021, 28(6):661-674.

[11] Ruiz i Altaba A. Hedgehog signaling and the Gli code in stem cells, cancer, and metastases. Sci Signal, 2011, 4(200).

[12] Michaud NR, Wang Y, McEachern KA, Jordan JJ, Mazzola AM, Hernandez A, Jalla S, Chesebrough JW, Hynes MJ, Belmonte MA, Wang L, Kang JS, Jovanovic J, Laing N, Jenkins DW, Hurt E, Liang M, Frantz C, Hollingsworth RE, Simeone DM, Blakey DC, Bedian V. Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Mol Cancer Ther, 2014, 13(2):386-398.

[13] Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, Sundaresan T, Pastorino S, Park JK, Mikolaenko I, Maric D, Eberhart CG, Fine HA. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res, 2005, 65(6):2353-2363.

[14] Wang J, Wang C, Meng Q, Li S, Sun X, Bo Y, Yao W. siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth. Mol Biol Rep, 2012, 39(3):2497-2503.

[15] Chen J, Kesari S, Rooney C, Strack PR, Chen J, Shen H, Wu L, Griffin JD. Inhibition of notch signaling blocks growth of glioblastoma cell lines and tumor neurospheres. Genes Cancer, 2010, 1(8):822-835.

[16] Zou Y, Cao Y, Yue Z, Liu J. Gamma-secretase inhibitor DAPT suppresses glioblastoma growth via uncoupling of tumor vessel density from vessel function. Clin Exp Med, 2013, 13(4):271-278.

[17] Kristoffersen K, Villingshøj M, Poulsen HS, Stockhausen MT. Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther, 2013, 14(7):625-637.

[18] Hai L, Zhang C, Li T, Zhou X, Liu B, Li S, Zhu M, Lin Y, Yu S, Zhang K, Ren B, Ming H, Huang Y, Chen L, Zhao P, Zhou H, Jiang T, Yang X. Notch1 is a prognostic factor that is distinctly activated in the classical and proneural subtype of glioblastoma and that promotes glioma cell survival via the NF-κB(p65) pathway. Cell Death Dis, 2018, 9(2):158.

[19] Wang Y, Wu J, Chen H, Yang Y, Xiao C, Yi X, Shi C, Zhong K, He H, Li Y, Wu Z, Zhou G, Rao Q, Wang X, Zhou X, Lomberk G, Liu B, Zhao J, Ge J, Zhou W, Chu X, Chen C, Zhou X, Wang L, Guan K, Qu L. Genome-wide CRISPR-Cas9 screen identified KLF11 as a druggable suppressor for sarcoma cancer stem cells. Sci Adv, 2021, 7(5).

[20] Zhang J, Wang S, Zhang D, He X, Wang X, Han H, Qin Y. Nanoparticle-based drug delivery systems to enhance cancer immunotherapy in solid tumors. Front Immunol, 2023, 14:1230893.